Henry Ford Hospital study: A MRSA strain linked to high death rates

October 31, 2009

A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study.

The study found that 50 percent of the patients infected with the strain died within 30 days compared to 11 percent of patients infected with other MRSA strains.

The average 30-day mortality rate for MRSA bloodstream infections ranges from 10 percent to 30 percent.

Researchers say the strain USA600 contains unique characteristics that may be linked to the high mortality rate. But they say it is unclear whether other factors like the patients' older age, diseases or the spread of infection contributed to the poor outcomes collectively or with other factors. The average age of patients with the USA600 strain was 64; the average age of patients with other MRSA strains was 52.

The study is being presented at the 47th annual meeting of the Infectious Diseases Society of America Oct. 29-Nov.1 in Philadelphia.

"While many MRSA strains are associated with poor outcomes, the USA600 strain has shown to be more lethal and cause high mortality rates," says Carol Moore, PharmD., a research investigator in Henry Ford's Division of Infectious Diseases and lead author of the study.

"In light of the potential for the spread of this virulent and resistant strain and its associated mortality, it is essential that more effort be directed to better understanding this strain to develop measures for managing it."

MRSA, or Methicillin-resistant Staphylococcus aureus, is a bacterium that is resistant to common antibiotics like penicillin. It can cause skin, bloodstream and surgical wound infections and pneumonia. The majority of infections occur among patients in hospitals or other health care settings, though a growing number of infections are being acquired by otherwise healthy people outside those settings.

MRSA strains can be resistant to many drugs, though they are typically susceptible to the antibiotic vancomycin. MRSA infections are often treated with vancomycin administered intravenously. The USA600 strain in this study was shown to be more resistant to vancomycin.
-end-
The study was funded by Henry Ford Hospital.

Henry Ford Health System

Related MRSA Articles from Brightsurf:

Widely available antibiotics could be used in the treatment of 'superbug' MRSA
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research from an international collaboration led by scientists at the University of Cambridge and the Wellcome Sanger Institute.

Computer model shows how to better control MRSA outbreaks
A research team led by scientists at the Columbia University Mailman School of Public Health report on a new method to help health officials control outbreaks of methicillin-resistant Staphylococcus aureus, or MRSA, a life-threatening antibiotic-resistant infection often seen in hospitals.

Using MRSA's strength against it
MRSA evolved to become a deadly killer because it's wily and resilient.

Livestock-associated MRSAfound among MRSA from humans
The survey results show more frequent detections and geographical dispersion of LA-MRSA in humans in the EU/EEA since 2007, and highlight the public health and veterinary importance of LA-MRSA as a 'One Health' issue.

Fighting MRSA with new membrane-busting compounds
Public health officials are increasingly concerned over methicillin-resistant Staphylococcus aureus (MRSA).

Know thy enemy: Kill MRSA with tailored chemistry
UConn medicinal chemists have developed experimental antibiotics that kill MRSA, a common and often deadly bacteria that causes skin, lung, and heart infections.

MRSA uses decoys to evade a last-resort antibiotic
The superbug MRSA uses decoys to evade a last-resort antibiotic, reveals new research.

Scientists find a salty way to kill MRSA
Scientists have discovered a new way to attack Staphylococcus aureus bacteria.

Experimental antibiotic treats deadly MRSA infection
A new experimental antibiotic developed by a team of scientists at Rutgers University successfully treats the deadly MRSA infection and restores the efficacy of a commonly prescribed antibiotic that has become ineffective against MRSA.

OU team develops new antibiotic to fight MRSA
A University of Oklahoma team of chemists has developed a new antibiotic formulation to fight the sometimes deadly staph infection caused by methicillin-resistant S. aureus or MRSA and other antibiotic-resistant infectious bacteria.

Read More: MRSA News and MRSA Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.